Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (9) | Back to Search
Robustness aspects of Continuous Direct Compressed HPMC based Extended Release Tablets
- In: Short Communications C1 on Monday, 22 May 2017, 13:30-15:00
- At: Stockholm (Sweden) (2017)
- Type: Presentation
- By: ABRAHMSéN-ALAMI, Susanna (AstraZeneca, Pharmaceutical Technology and Development, Mölndal, Sweden)
- Co-author(s): Satu Lakio: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
Pirjo Tajarobi: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
Håkan Wikström: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
Magnus Fransson: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
Tuomas Ervasti: School of Pharmacy, University of Eastern Finland, Kuopio, Finland
Simo-Pekka Simonaho: School of Pharmacy, University of Eastern Finland, Kuopio, Finland
Jarkko Ketolainen: School of Pharmacy, University of Eastern Finland, Kuopio, Finland
Staffan Folestad: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
Susanna Abrahmsén-Alami: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden - Abstract:
Backgrounds
Continuous manufacturing of drug products is an approach to intensify the efficiency of drug production. The ability to provide extended and robust drug release in vivo relies on assuring proper distribution of both drug substance and matrix former.Aims
The aim was to evaluate the combined effect of processing variables and compositional .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023